Average cost of drugs for extensively drug-resistant tuberculosis in Guatemala
Guatemala: Average cost of drugs for extensively drug-resistant tuberculosis was 11,910 constant 2022 US$ in 2024. ◆ Volatile
Average cost of drugs for extensively drug-resistant tuberculosis in Guatemala, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of drugs for extensively drug-resistant tuberculosis in Guatemala is 11,910 constant 2022 US$, measured in 2024. That is the highest value across all 7 years on record.
The figure is up 7.5% over ten years.
That places Guatemala 3rd out of 56 countries with data for 2024, putting it in the top 10%.
Average cost of drugs for extensively drug-resistant tuberculosis in Guatemala, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 11,075 constant 2022 US$ | — |
| 2019 | 11,075 constant 2022 US$ | +0.0% |
| 2020 | 2,042 constant 2022 US$ | -81.6% |
| 2021 | 2,042 constant 2022 US$ | +0.0% |
| 2022 | 2,042 constant 2022 US$ | +0.0% |
| 2023 | 11,910 constant 2022 US$ | +483.3% |
| 2024 | 11,910 constant 2022 US$ | +0.0% |
Guatemala compared with similar countries
- Guatemala's 11,910 constant 2022 US$ is above the median for upper middle income countries, which is 2,000 constant 2022 US$, 6.0× the median. (23 countries reporting)
- Guatemala's 11,910 constant 2022 US$ is above the median for Latin America & Caribbean, which is 3,884 constant 2022 US$, 3.1× the median. (9 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 11,075 constant 2022 US$ | 11,075 constant 2022 US$ | 11,075 constant 2022 US$ | 2 |
| 2020s | 5,989 constant 2022 US$ | 2,042 constant 2022 US$ | 11,910 constant 2022 US$ | 5 |
Countries ranked near Guatemala
More reference data data for Guatemala
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.9286 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 1.39 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 3.72 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.1246 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 3.72 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 3.11 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 1.9 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 7.68 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 18.61 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 0.6786 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Guatemala?
- Average cost of drugs for extensively drug-resistant tuberculosis in Guatemala was 11,910 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Guatemala?
- The highest recorded value was 11,910 constant 2022 US$ in 2023.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Guatemala?
- The lowest recorded value was 2,042 constant 2022 US$ in 2020.
- How does Guatemala rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Guatemala ranks 3rd out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Guatemala?
- Over the last ten years it is up 7.5%. The long-run trend across the full record is volatile.
- Where does this Guatemala data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 7 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.